Merck KGaA Rebif Faces Irreversible Decline; Avelumab Update Seen Soon
This article was originally published in The Pink Sheet Daily
Sales of the German multinational’s best-selling MS product sharply declined in the second quarter, but higher investment is likely to boost its research pipeline of early- and late-stage products.
You may also be interested in...
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.